BC Innovations | Jan 11, 2017
Product R&D

Now hear this

Most regenerative medicine companies are using stem cell therapies to replace and regrow damaged tissues, but development of stem cell therapies is complicated by manufacturing and regulatory challenges. Frequency Therapeutics Inc. is creating a next...
BC Week In Review | Apr 4, 2016
Clinical News

NeurotrophinCell: Phase IIb started

Living Cell began a double-blind, placebo-controlled, dose-ranging, New Zealand Phase IIb trial to evaluate NtCell in 18 patients. Living Cell Technologies Ltd. (ASX:LCT), Sydney, Australia   Product: NeurotrophinCell (NtCell)   Business: Neurology   Molecular target:...
BC Week In Review | Feb 22, 2016
Financial News

LCT completes private placement

Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia   Business: Gene/Cell therapy, Endocrine/Metabolic, Neurology   Date completed: 2016-02-16   Type: Private placement   Raised: A$2.8 million ($2 million)   Shares: 54.6 million   Price: A$0.05...
BC Week In Review | Feb 22, 2016
Financial News

LCT proposes private placement

Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia   Business: Gene/Cell therapy, Endocrine/Metabolic, Neurology   Date announced: 2016-02-16   Type: Private placement   To be raised: TBD   Shares: TBD   Price prior: A$0.06  ...
BC Innovations | Jan 7, 2016
Tools & Techniques

Islets of hope

The idea of using islet cell transplantation to treat diabetes has been simmering on the back burner for the last 15 years, with progress limited by two key obstacles: a shortage of donor cells, and...
BC Week In Review | Nov 9, 2015
Clinical News

NeurotrophinCell: Phase I/IIa data

Data from 4 PD patients in an open-label, New Zealand Phase I/IIa trial showed NtCell injected into the brain stopped disease progression and significantly improved neurological scores in all 4 patients at 42 weeks post-implant....
BC Week In Review | Oct 7, 2013
Clinical News

NeurotrophinCell: Phase I started

Living Cell began an open-label, New Zealand Phase I trial to evaluate NtCell injected into the brain in 4 patients who have been diagnosed with PD for >=4 years. An independent DSMB will evaluate 2-month...
BioCentury | Apr 22, 2013
Finance

The audiophiles

Sofinnova Partners and Sofinnova Ventures think audiology is the next ophthalmology - a former backwater that has become an investable space. Last week, the VCs came in as new investors in a CHF47.1 million ($50.7 million)...
BC Week In Review | Oct 24, 2011
Company News

LCT, Otsuka Pharmaceutical deal

Living Cell and Otsuka will establish a 50/50 JV, to be named Diatranz Otsuka Ltd., to develop and commercialize Living Cell's DiabeCell worldwide, except for China. Otsuka will contribute A$25 million ($25.9 million) to the...
BC Week In Review | Apr 25, 2011
Financial News

LCT completes placing

Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia   Business: Gene/Cell therapy, Endocrine, Neurology   Date completed: 4/12/11   Type: Placing   Raised: A$3 million (US$3.2 million)   Shares: 25 million   Price: A$0.12  ...
Items per page:
1 - 10 of 47
BC Innovations | Jan 11, 2017
Product R&D

Now hear this

Most regenerative medicine companies are using stem cell therapies to replace and regrow damaged tissues, but development of stem cell therapies is complicated by manufacturing and regulatory challenges. Frequency Therapeutics Inc. is creating a next...
BC Week In Review | Apr 4, 2016
Clinical News

NeurotrophinCell: Phase IIb started

Living Cell began a double-blind, placebo-controlled, dose-ranging, New Zealand Phase IIb trial to evaluate NtCell in 18 patients. Living Cell Technologies Ltd. (ASX:LCT), Sydney, Australia   Product: NeurotrophinCell (NtCell)   Business: Neurology   Molecular target:...
BC Week In Review | Feb 22, 2016
Financial News

LCT completes private placement

Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia   Business: Gene/Cell therapy, Endocrine/Metabolic, Neurology   Date completed: 2016-02-16   Type: Private placement   Raised: A$2.8 million ($2 million)   Shares: 54.6 million   Price: A$0.05...
BC Week In Review | Feb 22, 2016
Financial News

LCT proposes private placement

Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia   Business: Gene/Cell therapy, Endocrine/Metabolic, Neurology   Date announced: 2016-02-16   Type: Private placement   To be raised: TBD   Shares: TBD   Price prior: A$0.06  ...
BC Innovations | Jan 7, 2016
Tools & Techniques

Islets of hope

The idea of using islet cell transplantation to treat diabetes has been simmering on the back burner for the last 15 years, with progress limited by two key obstacles: a shortage of donor cells, and...
BC Week In Review | Nov 9, 2015
Clinical News

NeurotrophinCell: Phase I/IIa data

Data from 4 PD patients in an open-label, New Zealand Phase I/IIa trial showed NtCell injected into the brain stopped disease progression and significantly improved neurological scores in all 4 patients at 42 weeks post-implant....
BC Week In Review | Oct 7, 2013
Clinical News

NeurotrophinCell: Phase I started

Living Cell began an open-label, New Zealand Phase I trial to evaluate NtCell injected into the brain in 4 patients who have been diagnosed with PD for >=4 years. An independent DSMB will evaluate 2-month...
BioCentury | Apr 22, 2013
Finance

The audiophiles

Sofinnova Partners and Sofinnova Ventures think audiology is the next ophthalmology - a former backwater that has become an investable space. Last week, the VCs came in as new investors in a CHF47.1 million ($50.7 million)...
BC Week In Review | Oct 24, 2011
Company News

LCT, Otsuka Pharmaceutical deal

Living Cell and Otsuka will establish a 50/50 JV, to be named Diatranz Otsuka Ltd., to develop and commercialize Living Cell's DiabeCell worldwide, except for China. Otsuka will contribute A$25 million ($25.9 million) to the...
BC Week In Review | Apr 25, 2011
Financial News

LCT completes placing

Living Cell Technologies Ltd. (ASX:LCT; OTCQX:LVCLY), Sydney, Australia   Business: Gene/Cell therapy, Endocrine, Neurology   Date completed: 4/12/11   Type: Placing   Raised: A$3 million (US$3.2 million)   Shares: 25 million   Price: A$0.12  ...
Items per page:
1 - 10 of 47